Abstract:Background: tRNA-derived RNA fragments (tRFs) are a novel class of small ncRNA that are derived from precursor or mature tRNAs. Recently, the general relevance of their roles and clinical values in tumorigenesis, metastasis, and recurrence have been increasingly highlighted. However, there has been no specific systematic study to elucidate any potential clinical significance for these tRFs in prostate adenocarcinoma (PRAD), one of the most common and malignant cancers that threatens male health worldwide. Here, we investigate the clinical value of 5′-tRFs in PRAD. Methods: Small RNA sequencing data were analyzed to discover new 5′-tRFs biomarkers for PRAD. Machine learning algorithms were used to identify 5′-tRF classifiers to distinguish PRAD tumors from normal tissues. LASSO and Cox regression analyses were used to construct 5′-tRF prognostic predictive models. NMF and consensus clustering analyses were performed on 5′-tRF profiles to identify molecular subtypes of PRAD. Results: The overall levels of 5′-tRFs were significantly upregulated in the PRAD tumor samples compared to their adjacent normal samples. tRF classifiers composed of 13 5′-tRFs achieved AUC values as high as 0.963, showing high sensitivity and specificity in distinguishing PRAD tumors from normal samples. Multiple 5′-tRFs were identified as being associated with the PRAD prognosis. The tRF score, defined by a set of eight 5′-tRFs, was highly predictive of survival in PRAD patients. The combination of tRF and Gleason scores showed a significantly better performance than the Gleason score alone, suggesting that 5′-tRFs can offer PRAD patients additional and improved prognostic information. Four molecular subtypes of the PRAD tumor were identified based on their 5′-tRF expression profiles. Genetically, these 5′-tRFs PRAD tumor subtypes exhibited distinct genomic landscapes in tumor cells. Clinically, they showed marked differences in survival and clinicopathological features. Conclusions: 5′-tRFs are potential clinical biomarkers for the diagnosis, prognosis, and classification of tumor subtypes on a molecular level. These can help clinicians formulate personalized treatment plans for PRAD patients and may have similar potential applications for other disease types.

Emerging roles of tRNA-derived fragments in cancer

tRNA-derived RNA fragments in cancer: current status and future perspectives

tRNA‐derived fragments: Unveiling new roles and molecular mechanisms in cancer progression

Global Identification and Characterization of Trna-Derived RNA Fragment Landscapes Across Human Cancers

Role of Trna-Derived Fragments in Cancer: Novel Diagnostic and Therapeutic Targets Trfs in Cancer.

tRNA-derived fragments: Mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections

Extracellular vesicles-associated tRNA-derived fragments (tRFs): biogenesis, biological functions, and their role as potential biomarkers in human diseases

Relationship Between Trna-Derived Fragments and Human Cancers.

Roles of Trna-Derived Fragments in Human Cancers.

Research advances of tRNA-derived fragments in tumors

Oncotrf: An Online Resource For Exploration Of Trna-Derived Fragments In Human Cancers

Screening and Comprehensive Analysis of Cancer-Associated tRNA-Derived Fragments

Structural Characterizations and Biological Functions of tRFs

Emerging roles of tRNA in cancer.

Trna-Derived Fragments: Mechanism of Gene Regulation and Clinical Application in Lung Cancer.

tRNA-derived small RNAs: Mechanisms and potential roles in cancers

Trna-Derived RNA Fragments Are Novel Biomarkers for Diagnosis, Prognosis, and Tumor Subtypes in Prostate Cancer

Multiple regulatory roles of the transfer RNA-derived small RNAs in cancers

Transfer RNA-derived small RNA: A rising star in oncology

Trna-Derived Fragments As New Hallmarks of Aging and Age-related Diseases

Identification of Trna‑derived Fragments in Colon Cancer by Comprehensive Small RNA Sequencing